Our Market

 

 

The CRANE platform is intended for researchers in the field neurodegenerative diseases, but can potentially applied to other relevant areas of interest. By conducting their studies on the CRANE platform, researchers from academia, industry, hospitals and neurodegenerative  disease foundations will have the capacity to perform high throughput experiments with results that better represent the in-vivo environment of a diseased brain.  This will advance the battle against Alzheimer’s, and other neurological diseases.

Our platform is currently compatible for use with Multi Channel Systems’ MEA-2100 for in vivo recording. We intend to gather further funds from local business competitions and angel investing. Once these have been obtained, we intend to perform additional viability experiments on our own.

These tests will show the viability of our device as a “proof of concept” platform for drug testing.  In this stage of drug testing, pharmaceutical researchers would benefit from fast feedback on whether or not their compounds worked in their intended goals, creating a marked improvement over standard animal trials.  With CRANE, rapid feedback would quickly show the success or failure of a potential drug,  allowing resources to be intelligently allocated.

Once we have gathered sufficient proof of viability, we will sell our device to pharmaceutical companies. In the future, we will contact the Center for Drug Evaluation and Research (CDER), to receive general approval for use in downstream clinical trials.